Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress

OnKure Therapeutics, Inc.

2022-Q3 EPS reported -$1.82

Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.
Cash, equivalents and short-term investments $157.7M as of Sept 30, 2021.
Initiated STRIDE Phase 2b trial for REN001 in PMM; completed LC-FAOD Phase 1b enrollment.
Appointed Ashley Hall as Chief Development Officer; received US patent notice of allowance for REN001 into 2041.
Expects Phase 1b results for McArdle disease Q1 2022 and LC-FAOD Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.